NCT06791824 - Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia | Biotech Hunter

Enrollment

125

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Aplastic Anemia

Interventions

BIOLOGICAL

CM313(SC) injection

Phase IB: CM313(SC) administered at low dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results.

BIOLOGICAL

CM313(SC) injection

Phase IB: CM313(SC) administered at medium dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results.

BIOLOGICAL

CM313(SC) injection

Phase IB: CM313(SC) administered at high dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results.

Trial Locations (1)

Unknown

Institute of Hematology & Blood Diseases Hospital, Tianjin